Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2019

Open Access 01-12-2019 | Infliximab | Research article

Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients—immune-related candidate proteins affected by TNF blocking treatment

Authors: Johanna Estelius, Johan Lengqvist, Elena Ossipova, Helena Idborg, Erwan Le Maître, Magnus L. A. Andersson, Lou Brundin, Mohsen Khademi, Elisabet Svenungsson, Per-Johan Jakobsson, Jon Lampa

Published in: Arthritis Research & Therapy | Issue 1/2019

Login to get access

Abstract

Background

Signs of inflammation in cerebrospinal fluid (CSF) of rheumatoid arthritis patients correlate positively with fatigue, a central nervous system (CNS)-related symptom that can be partially suppressed by TNF blockade. This suggests a possible role for CNS inflammation in arthritis that may be affected by TNF blockade. We therefore investigated the effects of TNF blockade on the arthritis CSF proteome and how candidate proteins related to clinical measures of disease activity and inflammation.

Methods

Mass spectrometry-based quantitative proteomic analysis was performed on CSF from seven polyarthritis patients before and during infliximab treatment. Treatment-associated proteins were identified using univariate (Wilcoxon signed rank test) and multivariate (partial least squares discriminant analysis (PLS-DA)) strategies. Relations between selected candidate proteins and clinical measures were investigated using the Spearman correlations. Additionally, selected proteins were cross-referenced to other studies investigating human CSF in a thorough literature search to ensure feasibility of our results.

Results

Univariate analysis of arthritis CSF proteome revealed a decrease of 35 proteins, predominantly involved in inflammatory processes, following TNF blockade. Seven candidate proteins, Contactin-1 (CNTN1), fibrinogen gamma chain (FGG), hemopexin (HPX), cell adhesion molecule-3 (CADM3), alpha-1B-glycoprotein (A1BG), complement factor B (CFB), and beta-2-microglobulin (B2M), were selected for further studies based on identification by both univariate and multivariate analyses and reported detection in human CSF and known associations to arthritis. Decreased levels of FGG and CFB in CSF after treatment showed strong correlations with both erythrocyte sedimentation rate and disability scores, while CNTN1 and CADM3 were associated with pain.

Conclusion

Several immune-related proteins in the CSF of arthritis patients decreased during TNF blockade, including FGG and CFB that both correlated strongly with systemic inflammation. Our findings stress that also intrathecal inflammatory pathways are related to arthritis symptoms and may be affected by TNF blockade.
Appendix
Available only for authorised users
Literature
1.
Louati K, Berenbaum F. Fatigue in chronic inflammation - a link to pain pathways. Arthritis Res Ther. 2015;17:1–10.CrossRef
2.
Joaquim AF, Appenzeller S. Neuropsychiatric manifestations in rheumatoid arthritis. Autoimmun Rev. 2015;14:1116–22.PubMedCrossRef
3.
Sandberg MEC, Saevarsdottir S, Altawil R, Klareskog L, Alfredsson L, Lampa J. Remaining pain in spite of suppressed inflammation in early rheumatoid arthritis - long-term strongly increased risk for widespread pain and fatigue. Arthritis Rheumatol. 2014;66:S148.CrossRef
4.
Lampa J, Westman M, Kadetoff D, Agreus AN, Le Maitre E, Gillis-Haegerstrand C, Andersson M, Khademi M, Corr M, Christianson CA, et al. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc Natl Acad Sci U S A. 2012;109:12728–33.PubMedPubMedCentralCrossRef
5.
Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:581–92.PubMedCrossRef
6.
Belarbi K, Jopson T, Tweedie D, Arellano C, Luo WM, Greig NH, Rosi S. TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation. 2012;9:13.CrossRef
7.
Terrando N, Monaco C, Ma D, Foxwell BMJ, Feldmann M, Maze M. Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci. 2010;107:20518.PubMedCrossRef
8.
De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor alpha treatment: comparison of the efficacy of the tumour necrosis factor alpha blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. Panminerva Med. 2006;48:129–35.PubMed
9.
Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol. 2001;28:1605–14.PubMed
10.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932–9.PubMedCrossRef
11.
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromica-Ihle E, Kellner H, Krause A, Schneider M, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–93.PubMedCrossRef
12.
Antoni CE, Kavanagh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005;52:1227–36.PubMedCrossRef
13.
Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62:245–7.PubMedPubMedCentralCrossRef
14.
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–8.PubMed
15.
Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet’s syndrome. J Neurol Sci. 2008;272:99–105.PubMedCrossRef
16.
Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine. 2016;95:12.CrossRef
17.
Boyle DL, Jones TL, Hammaker D, Svensson CI, Rosengren S, Albani S, Sorkin L, Firestein GS. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med. 2006;3:1616–24.CrossRef
18.
Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, Williams R. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum. 2007;56:4015–23.PubMedCrossRef
19.
Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics. 2005;2:57–70.PubMedCrossRef
20.
Gineste C, Ho L, Pompl P, Bianchi M, Pasinetti GM. High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: effects of nimesulide. Drugs. 2003;63:23–9.PubMedCrossRef
21.
Baraniuk JN, Casado B, Maibach H, Clauw DJ, Pannell LK, Hess S. A chronic fatigue syndrome - related proteome in human cerebrospinal fluid. BMC Neurol. 2005;5:19.CrossRef
22.
Andersson M, Svenungsson E, Khademi M, Lampa J, Brundin L, Wallstrom E. No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab. Ann Rheum Dis. 2006;65:1237–40.PubMedPubMedCentralCrossRef
23.
Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, et al. T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 2004;172:7169–76.PubMedCrossRef
24.
Prevoo ML, vant HMA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.PubMedCrossRef
25.
26.
Bruce B, Fries JF. The health assessment questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14–8.PubMed
27.
Pan W, Banks WA, Kastin AJ. Permeability of the blood–brain and blood–spinal cord barriers to interferons. J Neuroimmunol. 1997;76:105–11.CrossRef
28.
Rochfort KD, Cummins PM. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. Biochem Soc Trans. 2015;43:702–6.PubMedCrossRef
29.
Andersson M, Alvarezcermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis - a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897–902.PubMedPubMedCentralCrossRef
30.
Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders .1. Establishment of reference intervals. Scand J Clin Lab Invest. 1977;37:385–90.PubMedCrossRef
31.
Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004;104:29–45.PubMedCrossRef
32.
Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:373–9.PubMed
33.
Chen YC, Wang PW, Pan TL, Bazylak G, Shen JJ. Proteomic analysis of plasma to reveal the impact of short-term etanercept therapy in pediatric patients with enthesitis-related arthritis: a case report. Comb Chem High Throughput Screen. 2010;13:469–81.PubMedCrossRef
34.
Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34:43–62.PubMedCrossRef
35.
Finnegan S, Robson J, Scaife C, McAllister C, Pennington SR, Gibson DS, Rooney ME. Synovial membrane protein expression differs between juvenile idiopathic arthritis subtypes in early disease. Arthritis Res Ther. 2014;16:12.CrossRef
36.
Biswas S, Sharma S, Saroha A, Bhakuni DS, Malhotra R, Zahur M, Oellerich M, Das HR, Asif AR. Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS One. 2013;8(2):e56246.PubMedPubMedCentralCrossRef
37.
Takada Y, Ono Y, Sagusa J, Mitsiades C, Mitsiades N, Tsai J, He Y, Maningding E, Coleman A, Ramirez-Maverakis D, et al. A T cell-binding fragment of fibrinogen can prevent autoimmunity. J Autoimmun. 2010;34:453–9.PubMedCrossRef
38.
Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, Moller T, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci. 2017;20:1162.CrossRef
39.
Levesque S, Taetzsch T, Lull ME, Johnson JA, McGraw C, Block ML. The role of MAC1 in diesel exhaust particle-induced microglial activation and loss of dopaminergic neuron function. J Neurochem. 2013;125:756–65.PubMedPubMedCentralCrossRef
40.
Hu XM, Zhang D, Pang H, Caudle WM, Li YC, Gao HM, Liu YX, Qian L, Wilson B, Di Monte DA, et al. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. J Immunol. 2008;181:7194–204.PubMedPubMedCentralCrossRef
41.
Lind AL, Khoonsari PE, Sjodin M, Katila L, Wetterhall M, Gordh T, Kultima K. Spinal cord stimulation alters protein levels in the cerebrospinal fluid of neuropathic pain patients: a proteomic mass spectrometric analysis. Neuromodulation. 2016;19:549–62.PubMedCrossRef
42.
Dityatev A, Bukalo O, Schachner M. Modulation of synaptic transmission and plasticity by cell adhesion and repulsion molecules. Neuron Glia Biol. 2008;4:197–209.PubMedCrossRef
43.
Gonzalez-Pena D, Nixon SE, O'Connor JC, Southey BR, Lawson MA, McCusker RH, Borras T, Machuca D, Hernandez AG, Dantzer R, et al. Microglia transcriptome changes in a model of depressive behavior after immune challenge. PLoS One. 2016;11:28.
44.
Shah BS, Rush AM, Liu SJ, Tyrrell L, Black JA, Dib-Hajj SD, Waxman SG. Contactin associates with sodium channel Na(v)1.3 in native tissues and increases channel density at the cell surface. J Neurosci. 2004;24:7387–99.PubMedCrossRef
45.
Tolosano E, Altruda F. Hemopexin: structure, function, and regulation. DNA Cell Biol. 2002;21:297–306.PubMedCrossRef
46.
Lee YS, Kim AY, Choi JW, Kim M, Yasue S, Son HJ, Masuzaki H, Park KS, Kim JB. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol. 2008;22:2176–89.PubMedPubMedCentralCrossRef
47.
48.
Lim TKY, Anderson KM, Hari P, Di Falco M, Reihsen TE, Wilcox GL, Belani KG, LaBoissiere S, Pinto MR, Beebe DS, et al. Evidence for a role of nerve injury in painful intervertebral disc degeneration: a cross-sectional proteomic analysis of human cerebrospinal fluid. J Pain. 2017;18(10):1253–69.PubMedPubMedCentralCrossRef
49.
Ulreich A, Rainer F, Sedlmayr P, Leb G. Correlations of neopterin and beta-2-microglobulin with the disease-activity in rheumatoid arthritis. Acta Med Austriaca. 1988;15:145–8.PubMed
50.
Ponnuraj K, Xu YY, Macon K, Moore D, Volanakis JE, Narayana SVL. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell. 2004;14:17–28.PubMedCrossRef
51.
Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ. Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol. 2007;37:1691–701.PubMedCrossRef
52.
Huang Y, Krein PM, Muruve DA, Winston BW. Complement factor B gene regulation: synergistic effects of TNF-alpha and IFN-gamma in macrophages. J Immunol. 2002;169:2627–35.PubMedCrossRef
53.
Goring K, Huang Y, Mowat C, Leger C, Lim TH, Zaheer R, Mok D, Tibbles LA, Zygun D, Winston BW. Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C. Am J Phys Cell Phys. 2009;296:C1140–50.CrossRef
54.
Tan WX, Pu YY, Shao Q, Fang X, Han DX, Zhao M, Cao L. Insulin-like growth factor-binding protein 7 is up-regulated during EAE and inhibits the differentiation of oligodendrocyte precursor cells. Biochem Biophys Res Commun. 2015;460:639–44.PubMedCrossRef
55.
Nishimura T, Kubosaki A, Ito Y, Notkins AL. Disturbances in the secretion of neurotransmitter in IA-2/IA-2 null mice: changes in behavior, learning and lifespan. Neuroscience. 2009;159:427–37.PubMedPubMedCentralCrossRef
56.
Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack CR, Tosun D, Weiner M, Alzheimers Dis Neuroimaging I. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging. 2014;35:614–22.PubMedCrossRef
57.
Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, Valesini G. Beta(2)-glycoprotein I (beta(2)-GPI) mRNA is expressed by several cell types involved in antiphospholipid syndrome-related tissue damage. Clin Exp Immunol. 1999;115:214–9.PubMedPubMedCentralCrossRef
58.
Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, Degen JL, Akassoglou K. The fibrin-derived gamma(377-395) peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 2007;204:571–82.PubMedPubMedCentralCrossRef
59.
Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol. 1997;24:372–6.PubMed
60.
Olausson P, Ghafouri B, Bäckryd E, Gerdle B. Clear differences in cerebrospinal fluid proteome between women with chronic widespread pain and healthy women – a multivariate explorative cross-sectional study. J Pain Res. 2017;10:575–90.PubMedPubMedCentralCrossRef
61.
Caudie C, Bancel J, Dupont M, Matanza D, Poitevin F, Honnorat J. CSF levels and diagnostic utility of cerebrospinal fluid beta 2-microglobulin. Ann Biol Clin. 2005;63:631–7.
62.
Manral P, Sharma P, Hariprasad G, Chandralekha TM, Srinivasan A. Can apolipoproteins and complement factors be biomarkers of Alzheimer’s disease? Curr Alzheimer Res. 2012;9:935–43.PubMedCrossRef
63.
Li Y, Qin ZY, Yang MC, Qin YJ, Lin CZ, Liu SL. Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients. J Cell Biochem. 2011;112:1930–7.PubMedCrossRef
64.
Hahl P, Davis T, Washburn C, Rogers JT, Smith A. Mechanisms of neuroprotection by hemopexin: modeling the control of heme and iron homeostasis in brain neurons in inflammatory states. J Neurochem. 2013;125:89–101.PubMedCrossRef
65.
Saso L, Leone MG, Mo MY, Grippa E, Cheng CY, Silvestrini B. Differential changes in alpha(2)-macroglobulin and hemopexin in brain and liver in response to acute inflammation. Biochemistry-Moscow. 1999;64:839–44.PubMed
Metadata
Title
Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients—immune-related candidate proteins affected by TNF blocking treatment
Authors
Johanna Estelius
Johan Lengqvist
Elena Ossipova
Helena Idborg
Erwan Le Maître
Magnus L. A. Andersson
Lou Brundin
Mohsen Khademi
Elisabet Svenungsson
Per-Johan Jakobsson
Jon Lampa
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2019
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-019-1846-6

Other articles of this Issue 1/2019

Arthritis Research & Therapy 1/2019 Go to the issue

Research article

Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis

Research article

A search to the target tissue in which RA-specific inflammation starts: a detailed MRI study to improve identification of RA-specific features in the phase of clinically suspect arthralgia

Research article

Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis

Research article

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

Research article

A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin

Research article

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits